Immunai

Oct 16, 2025 ·

www.calcalistech.com

growth-positive

AI biotech expands partnership after uncovering novel immune target with its machine learning platform.

Immunai, an Israeli AI biotech company, has entered into a new agreement with AstraZeneca to develop a novel therapeutic target for inflammatory bowel disease (IBD). This partnership leverages Immunais Immunodynamics Engine (IDE) and its proprietary immune cell atlas, AMICA, which integrates single-cell multi-omics data with machine learning. AstraZeneca will have exclusive rights to develop and commercialize therapeutics aimed at the newly identified target, with Immunai receiving an upfront payment and potential earnings of up to $85 million based on development milestones. This agreement marks a significant milestone in Immunais ongoing collaboration with AstraZeneca, which began in 2022 and included an $18 million investment in 2024 to enhance oncology clinical trials.

PartnersInvestment

Nov 14, 2024 ·

www.calcalistech.com

growth-positive

Immunai and Teva launch multi-tear AI collaboration for smarter drug development | CTech

Immunai, an AI biotech company specializing in mapping the human immune system, has announced a multi-year collaboration with Teva Pharmaceuticals. This partnership aims to enhance clinical decision-making in Tevas immunology trials using Immunais proprietary immune cell atlas and AI model. The collaboration will focus on drug mechanism of action, dose selection, and biomarker analyses. This reflects Immunais ongoing efforts to streamline drug development processes. The collaboration is expected to provide insights into patient responses and treatment mechanisms, optimizing clinical trials and improving patient outcomes. Immunai recently announced a similar collaboration with AstraZeneca, valued at $18 million. Immunai, which employs 170 people, raised a $215 million Series B at a valuation of just over $1 billion in 2021.

Partners

Nov 14, 2024 ·

www.calcalistech.com

growth-positive

The partnership will utilize Immunai’s cutting-edge immune system mapping tools to enhance precision in immunology and oncology trials.

Immunai, an AI biotech company specializing in mapping the human immune system, has entered a multi-year collaboration with Teva Pharmaceuticals. This partnership aims to enhance Tevas Immunology and Immuno-oncology programs by leveraging Immunais immune cell atlas and AI model to improve clinical decision-making. The collaboration will focus on drug mechanism of action, dose selection, and biomarker analyses. This partnership reflects Immunais ongoing efforts to streamline drug development and deliver new therapies to patients. Additionally, Immunai recently announced a collaboration with AstraZeneca, valued at $18 million, to enhance cancer drug trials. Immunai has raised a total of $295 million, including a $215 million Series B round in 2021, with a valuation of just over $1 billion.

Partners

Sep 26, 2024 ·

www.calcalistech.com

growth-positive

The collaboration will focus on clinical decision-making, including dose selection, elucidating mechanisms of action, patient responder vs. non-responder analysis, and biomarker identification, by leveraging the Israeli biotech unicorn’s AI model of the immune system.

Israeli biotech startup Immunai has announced a multi-year collaboration with AstraZeneca, focusing on clinical decision-making and leveraging Immunais AI model of the immune system. Immunai will receive $18 million for the initial phase, with AstraZeneca having the option to extend the collaboration. The partnership aims to improve clinical trial success rates and R&D productivity. Immunai, which employs 170 people, raised a $215 million Series B at a valuation of just over $1 billion in 2021. This collaboration is part of AstraZenecas broader strategy to use AI in drug discovery and development.

PartnersInvestment

Sep 26, 2024 ·

en.globes.co.il

growth-positive

The agreement is worth an initial $18 million to Immunai, developer of an AI-based model for making drug development more efficient.

Israeli company Immunai, which develops AI-based tools for drug discovery, has entered into a strategic agreement with AstraZeneca. The deal is initially worth $18 million, but its significance lies in the planned multi-year collaboration between the two companies. Immunais platform, which models the human immune system, aims to improve the efficiency of drug development. The company has raised $300 million to date, including $215 million in a single round in 2021, and currently employs 170 people. AstraZenecas chief data scientist highlighted the potential of Immunais platform to enhance their R&D strategy.

PartnersInvestment

Oct 27, 2021 ·

techcrunch.com

growth-positive

Immunai announces a $215M Series B as its 'immune cell atlas' matures

Biotech startup Immunai has raised $215 million in a series B funding round, bringing its total funding to $295 million. The company has been building a large data set of clinical immunological information to map out how the immune system functions. It uses machine learning to identify drug targets, predict patient responses, and develop cell therapies. Immunais data set, called the Annotated Multi-omic Immune Cell Atlas (AMICA), is claimed to be the largest in the world. The funding will be used to expand the workforce, enrich the data set, and strengthen the companys infrastructure. Immunai has collaborated with over 30 companies and academic institutions and has made two major acquisitions to accelerate the growth of its database.

Investment

Aug 1, 2021 ·

www.startupticker.ch

growth-positive

Nebion becomes a subsidiary of New-York based Immunai

Immunai has announced the acquisition of Swiss bioinformatics company Nebion to expand its discovery and drug development capabilities. Nebion will become a wholly-owned subsidiary operating under the same name. The acquisition will allow Immunai to incorporate Nebions curated public datasets to improve its machine learning models and find drug targets. Immunai has also brought on renowned executives, including Robert Langer, Jacques Banchereau, and Mark Jacobstein. Immunai has raised over $90M in capital to date.

Acquisition

Jul 19, 2021 ·

www.israel21c.org

growth-positive

Creating a vital map of the human immune system

Immunai, a Tel Aviv-based company, is mapping the human immune system to understand how it fights diseases and develop new drugs. The company uses a granular map of the immune system to identify patterns and develop therapies. Immunai is working with CAR-T cells for its initial treatments and has acquired Dropprint Genomics to enhance its drug development capabilities. The company has raised $80 million in funding and has a multidisciplinary team of experts. Immunai aims to study immune-related diseases together to find connections and accelerate learning. The company believes that mapping the immune system is only the first step and plans to use the map to reprogram the immune system. Immunai has been recognized as one of the most promising companies and is focused on driving change through data and software.

PartnersInvestment

Mar 25, 2021 ·

www.webwire.com

growth-positive

Immunai Acquires Dropprint Genomics and Strengthens Leadership Team with Experts in Immunology to Expand Target Discovery Capabilities

Immunai, a biotech company, has announced its acquisition of Dropprint Genomics, a single-cell genomics software company. The acquisition will support Immunais work in single cell functional genomics and the development of new therapies. Immunai has also expanded its leadership team and scientific advisory board. The company has raised $80M in funding from various investors.

AcquisitionExpand

Feb 11, 2021 ·

techcrunch.com

growth-positive

Immunai raises $60M as it expands from improving immune therapies to discovering new ones, too

Biotech startup Immunai has raised $60 million in Series A funding, bringing its total raised to over $80 million. The company has established the largest database in the world for single cell immunity characteristics and has used its machine learning-powered platform to enhance existing immunotherapies. With the new funding, Immunai plans to expand into the development of new therapies based on its data and ML. The company uses a multiomic approach to analyze different types of biological data. Immunai has partnerships with leading immunological research organizations and aims to create new drugs based on its understanding of the human immune profile.

Investment

Dec 16, 2020 ·

medcitynews.com

growth-positive

Immunai joins 10x Genomics program to boost drug development

Immunai, a startup specializing in artificial intelligence and single-cell biology, has partnered with 10x Genomics to provide drugmakers with a better view of how a patients immune system responds to therapy. The partnership allows Immunai to become one of the first certified service providers for 10x Genomics in North America. By combining their technologies, the two companies aim to improve the understanding of the immune system and identify new potential drug combinations. Immunai, which emerged from stealth mode with $20 million in seed funding, has customers including drug companies and academic research institutions. The companys technology offers a more detailed look at cells and allows for the analysis of single-cell behavior on a larger scale.

Partners

Sep 23, 2020 ·

en.globes.co.il

growth-positive

The startup databasing our immune system

Immunai is building a database to profile the interactions between immune system cells in states of health and disease. The company aims to develop drugs based on immune system manipulation in a more efficient and customized way. It generates revenue by providing access to its database to pharmaceutical companies and is expected to announce a joint development agreement with a major pharmaceutical company. Immunais technology is based on an AI system and unique capabilities for profiling single-cell activity. The company has raised $20 million from Viola Ventures and TLV Partners and has 30 employees in Tel Aviv.

PartnersInvestment

May 14, 2020 ·

en.globes.co.il

growth-positive

Immune system mapping co Immunai raises $20m

Immunai, an Israeli-US personalized therapeutics company, has raised $20 million in funding for the development of its system for adapting treatments and accelerating drug development. The company uses machine learning and genetic sequencing technology to build a broad immunological database, aiming to make the effect of cancer treatments targeting the immune system more predictable. The funding round was led by Viola Ventures and TLV Partners. Immunai employs over 30 people in Tel Aviv and New York and collaborates with leading hospitals and pharmaceutical companies.

InvestmentExpand

Total funding	$295M
Last funding	$215M
Stage	B
Rounds	3
Investors	14

Website	www.immunai.com
LinkedIn	LinkedIn
Twitter	Twitter
Careers	Careers page

Employees (range)	51-200
Exact count	192
Team members	3

Confidence	91/100
Missing	markets, not claimed
BI Verification	Maor Perlov
Registrar ID	515981934
Crunchbase	immunai
Creator	Yotam Maman
Creator email	yotamm1988@gmail.com
Last updater	Maor Perlov
Updater email	maorperlov@gmail.com
Last update	2021-10-31T00:00:00.000Z
Created	2019-10-02T00:00:00.000Z

Immunai Overview

Cumulative Funding Raised Over Time ($)

Latest News

Funding

Team Members

Web & Social Links

Locations

Photos & Videos

Immunai Business

Sector

Target Customer

Core Technology

Tags (15)

Immunai Financials

Cumulative Funding Raised Over Time ($)

Private Equity Funding

Mergers & Acquisitions

Immunai Lifecycle

Cumulative Funding Raised Over Time

All Events

Immunai News

Immunai Team

Employee Info

Similar Companies

Immunai Internal

Recent Updates

Admin Info

Immunai

Immunai Overview

Cumulative Funding Raised Over Time ($)

Latest News

Funding

Team Members

Web & Social Links

Locations

Photos & Videos

Immunai Business

Sector

Target Customer

Core Technology

Tags (15)

Immunai Financials

Cumulative Funding Raised Over Time ($)

Private Equity Funding

Mergers & Acquisitions

Immunai Lifecycle

Cumulative Funding Raised Over Time

All Events

Immunai News

Immunai Team

Employee Info

Similar Companies

Immunai Internal

Recent Updates

Admin Info

Generate Slim Page